Epirus OTC Stock Performance

EPRSQ -  USA Stock  

USD 0.0001  0.00  0.00%

The firm shows a Beta (market volatility) of -0.3241, which means possible diversification benefits within a given portfolio. Let's try to break down what Epirus's beta means in this case. As returns on the market increase, returns on owning Epirus Biopharm are expected to decrease at a much lower rate. During the bear market, Epirus Biopharm is likely to outperform the market. Even though it is essential to pay attention to Epirus Biopharm historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards predicting any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Epirus Biopharm exposes twenty-one different technical indicators, which can help you to evaluate its performance. Epirus Biopharm has an expected return of -0.45%. Please be advised to confirm Epirus Biopharm semi deviation, jensen alpha, as well as the relationship between the Jensen Alpha and semi variance to decide if Epirus Biopharm performance from the past will be repeated at some point in the near future.

Epirus O TC Stock Performance 

 
Refresh
 Epirus Performance
0 of 100
Over the last 90 days Epirus Biopharm has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in November 2021. The recent disarray may also be a sign of long period up-swing for the firm insiders. ...more

Epirus Price Channel

Quick Ratio0.64
Fifty Two Week Low0.0001
Fifty Two Week High0.2400

Epirus Biopharm Relative Risk vs. Return Landscape

If you would invest  0.65  in Epirus Biopharm on July 25, 2021 and sell it today you would lose (0.64)  from holding Epirus Biopharm or give up 98.46% of portfolio value over 90 days. Epirus Biopharm is currently producing negative expected returns and takes up 21.2255% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Epirus, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days.
 Daily Expected Return (%) 
      Risk (%) 
Assuming the 90 days horizon Epirus Biopharm is expected to under-perform the market. In addition to that, the company is 29.77 times more volatile than its market benchmark. It trades about -0.02 of its total potential returns per unit of risk. The DOW is currently generating roughly 0.04 per unit of volatility.

Epirus Biopharm Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Epirus Biopharm's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Epirus Biopharm, and traders can use it to determine the average amount a Epirus Biopharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.0211

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsEPRSQ
Estimated Market Risk
 21.23
  actual daily
 
 96 %
of total potential
 
9696
Expected Return
 -0.45
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.02
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Epirus Biopharm is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Epirus Biopharm by adding it to a well-diversified portfolio.

About Epirus Biopharm Performance

To evaluate Epirus Biopharm OTC Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Epirus Biopharm generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Epirus OTC Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Epirus Biopharm stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Epirus's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Return on Investment(132.36) (142.81) 
Return on Average Assets(97.07) (104.74) 
Return on Average Equity(174.54) (188.32) 
EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts. Epirus Biopharm operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 73 people.

Things to note about Epirus Biopharm

Checking the ongoing alerts about Epirus Biopharm for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Epirus Biopharm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Epirus Biopharm Alerts

Equity Alerts and Improvement Suggestions

Epirus Biopharm generated a negative expected return over the last 90 days
Epirus Biopharm has high historical volatility and very poor performance
Epirus Biopharm has some characteristics of a very speculative penny stock
Epirus Biopharm has a very high chance of going through financial distress in the upcoming years
The company has accumulated 14.85 M in total debt with debt to equity ratio (D/E) of 0.57, which is about average as compared to similar companies. Epirus Biopharm has a current ratio of 0.77, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
The entity reported the revenue of 1.48 M. Net Loss for the year was (60.93 M) with profit before overhead, payroll, taxes, and interest of 576 K.
Epirus Biopharm has accumulated about 20.86 M in cash with (49.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Epirus Biopharm has a frail financial position based on the latest SEC disclosures
Continue to Investing Opportunities. Note that the Epirus Biopharm information on this page should be used as a complementary analysis to other Epirus Biopharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Epirus OTC Stock analysis

When running Epirus Biopharm price analysis, check to measure Epirus Biopharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Epirus Biopharm is operating at the current time. Most of Epirus Biopharm's value examination focuses on studying past and present price action to predict the probability of Epirus Biopharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Epirus Biopharm's price. Additionally, you may evaluate how the addition of Epirus Biopharm to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
The market value of Epirus Biopharm is measured differently than its book value, which is the value of Epirus that is recorded on the company's balance sheet. Investors also form their own opinion of Epirus Biopharm's value that differs from its market value or its book value, called intrinsic value, which is Epirus Biopharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Epirus Biopharm's market value can be influenced by many factors that don't directly affect Epirus Biopharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Epirus Biopharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Epirus Biopharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Epirus Biopharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.